echinocandin


Also found in: Wikipedia.

echinocandin

(ē-kī-nō-kan'din),
A class of antifungal compounds targeting the fungal cell wall. Action is by specific and noncompetitive inhibition of the (1,3)-β-d-glucan synthase enzyme complex that forms glucan polymers; a major component of the fungal cell wall in several pathogenic fungi.

echinocandin

(ē-kī″nō-kan′din) [Gr. echinos, hedgehog, sea urchin, + Cand(ida albicans) + -in]
Any of a class of antifungal drugs that block the synthesis of the fungal cell wall.
References in periodicals archive ?
Rezafungin is a novel, once-weekly echinocandin antifungal being developed for the first-line treatment of candidemia and invasive candidiasis as well as for the prophylaxis of invasive fungal infections in patients undergoing allogeneic blood and marrow transplantation, for which no new therapies have been approved in over 13 years.
Cidara is currently advancing its novel echinocandin antifungal, rezafungin acetate, in a Phase 3 clinical trial for the first-line treatment of candidemia and/or invasive candidiasis (ReSTORE).
In addition to CVC removal and its timing, the following variables were analyzed as potential factors associated with 30-day mortality: age, sex, APACHE II score (calculated on the day of the incident candidemia), concomitant medical conditions (cancer, diabetes, renal failure, cardiac disease, lung disease, cirrhosis), recent surgery (of any type requiring any anesthesia other than local anesthesia within three months prior to the incident candidemia), dialysis, mucositis, neutropenia (<500neutrophils/[mm.sup.3]), receipt of corticosteroids or total parenteral nutrition within 14 days before the incident candidemia, Candida species, and antifungal drug class (azole, amphotericin B or echinocandin).
Activity of contemporary antifungal agents, including the novel echinocandin anidulafungin, tested against Candida spp., Cryptococcus spp.
Overall, 28 (30%) were resistant to fluconazole, 20 (22%) to amphotericin B, one (1%) to anidulafungin (an echinocandin), and one to both amphotericin B and anidulafungin.
Therapeutic Options in the Management of Echinocandin Resistant Candida Species
Echinocandin (caspofungin, anidulafungin, micafungin) or fluconazole is recommended for empirical antifungal therapy.
These include the polyene group that encompasses amphotericin B deoxycholate and its lipid formulations (liposomal amphotericin B, amphotericin B lipid complex, and amphotericin B cholesteryl sulfate complex); the nucleoside analogue flucytosine; the triazoles which include fluconazole and voriconazole; and the most recently developed echinocandin class, which includes caspofungin, micafungin, and anidulafungin.
Empiric combination therapy with an azole + echinocandin was chosen to cover possible endemic fungi and invasive aspergillosis.
parapsilosis (a Candida species with higher intrinsic echinocandin MIC values) RZF was 8- to >1,024-fold more potent than TER against all strains tested, in both media types (median 64-fold more potent).
Caspofungin, an echinocandin drug, is used clinically for the invasive fungal disease.